Short single-speaker segment (Michigan-based) describing efforts to detect risk of future neurodegenerative disease—notably Alzheimer’s—decades in advance using quantitative MRI approaches. Speaker emphasizes current practice waits until mild cognitive impairment manifests, by which point effective drug interventions are lacking; early identification before symptoms could enable preventative interventions leveraging neuroplasticity.
Chapters
So I want to talk to you about something really exciting that's available in Michigan. It's about detecting the possibility of developing brain disease down the road, decades in advance. We know that there's three causes of death that are probably preventable in most people. Cardiovascular disease, cancer, and neurodegeneration, also known as dementia. And one of the common ones is Alzheimer's. And an inherent problem is we don't really intervene on Alzheimer's until people have symptoms. We call that mild cognitive impairment, where somebody's showing signs of dementia and. And then eventually they have Alzheimer's. We really don't have effective drugs for that right now. But in the early preventative stage, when somebody is getting before they're at the neurocognitive decline symptoms, they don't have mild cognitive impairment. The brain is plastic, meaning that it can grow back. It's called neuroplasticity. And the brain can spring back. But we don't really know who needs to do the interventions or what interventions are needed unless we identify the people that have risk for neurocognitive decline.